Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 30:12:1512385.
doi: 10.3389/fcvm.2025.1512385. eCollection 2025.

Qu-shi-hua-tan decoction's efficacy and safety for patients with angina following coronary revascularization: a randomized, double-blind, placebo-controlled trial study protocol

Wenjing Xu  1 , Jingwei Wen  1 , Xijiu Li  1 , Xiaoqing Li  1 , Yan Zhang  1 , Weihui Lu  1   2   3   4
Affiliations

Qu-shi-hua-tan decoction's efficacy and safety for patients with angina following coronary revascularization: a randomized, double-blind, placebo-controlled trial study protocol

Wenjing Xu et al. Front Cardiovasc Med. .

Abstract

Introduction: The Qu-shi-hua-tan decoction (QSHTD), formulated by academician Chen Keji, is an empirical decoction for coronary heart disease (CHD). We conducted a randomized controlled trial to assess the effectiveness and safety of QSHTD in managing angina after coronary revascularization (AACR) in CHD patients.

Methods and design: This double-blind randomized controlled trial will be conducted at Guangdong Provincial Hospital of Traditional Chinese Medicine. We will allocate 98 qualified participants to either the experimental or control group in a 1:1 ratio through random selection. The experimental group will be given standard care along with QSHTD, whereas the control group will receive standard care and a placebo. The study will span 26 weeks, consisting of a 2-week initial phase, a 12-week intervention phase, and a 12-week monitoring phase. The main outcome measure will be myocardial blood flow (MBF) assessed using adenosine stress real-time myocardial perfusion echocardiography (RTMPE). The secondary outcomes will be Canadian Cardiovascular Sociation Classification, Seattle Angina Questionnaire, Traditional Chinese Medicine (TCM) symptom evaluation; and major adverse cardiac events (MACE).

Discussion: This study seeks to deliver compelling proof of the superior methodological and reporting standards of QSHTD's effectiveness and safety within AACR treatment.

Clinical trial registration: Chinese Clinical Trial Registration Center [www.chictr.org.cn]. The trial was registered on November 26, 2020 [ChiCTR2000040270].

Keywords: Traditional Chinese Medicine; coronary heart disease; protocol; qu-shi-hua-tan decoction; randomized controlled trial.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

Figures

Figure 1
Figure 1
Study flowchart.
See this image and copyright information in PMC

References

    1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. (2020) 76(25):2982–3021. 10.1016/j.jacc.2020.11.010 - DOI - PMC - PubMed
    1. The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on cardiovascular health and diseases in China 2022: an updated summary. Chin Circ J. (2023) 38(6):583–612.
    1. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. (2022) 145(3):e18–114. 10.1161/CIR.0000000000001038 - DOI - PubMed
    1. Crea F, Bairey Merz CN, Beltrame JF, Berry C, Camici PG, Kaski JC, et al. Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization. Eur Heart J. (2019) 40(29):2455–62. 10.1093/eurheartj/ehy857 - DOI - PubMed
    1. Ajmal M, Chatterjee A, Acharya D. Persistent or recurrent angina following percutaneous coronary revascularization. Curr Cardiol Rep. (2022) 24(12):1837–48. 10.1007/s11886-022-01820-3 - DOI - PubMed

LinkOut - more resources